|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun M: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008.
|
|
2
|
Matsuda T, Marugame T, Kamo K, Katanoda K,
Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan
in 2002: based on data from 11 population-based cancer registries.
Jpn J Clin Oncol. 38:641–648. 2008.
|
|
3
|
Nonn L, Ananthanarayanan V and Gann PH:
Evidence for field cancerization of the prostate. Prostate.
69:1470–1479. 2009.
|
|
4
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003.
|
|
5
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005.
|
|
6
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
|
|
7
|
Gu G, Yuan J, Wills M and Kasper S:
Prostate cancer cells with stem cell characteristics reconstitute
the original human tumor in vivo. Cancer Res. 67:4807–4815.
2007.
|
|
8
|
Miki J, Furusato B, Li H, Gu Y, Takahashi
H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007.
|
|
9
|
Chambers I, Colby D, Robertson M, Nichols
J, Lee S, Tweedie S and Smith A: Functional expression cloning of
Nanog, a pluripotency sustaining factor in embryonic stem cells.
Cell. 113:643–655. 2003.
|
|
10
|
Mitsui K, Tokuzawa Y, Itoh H, Segawa K,
Murakami M, Takahashi K, Maruyama M, Maeda M and Yamanaka S: The
homeoprotein Nanog is required for maintenance of pluripotency in
mouse epiblast and ES cells. Cell. 113:631–642. 2003.
|
|
11
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008.
|
|
12
|
Santagata S, Ligon KL and Hornick JL:
Embryonic stem cell transcription factor signatures in the
diagnosis of primary and metastatic germ cell tumors. Am J Surg
Pathol. 31:836–845. 2007.
|
|
13
|
Gong C, Liao H, Guo F, Qin L and Qi J:
Implication of expression of Nanog in prostate cancer cells and
their stem cells. J Huazhong Univ Sci Technolog Med Sci.
32:242–246. 2012.
|
|
14
|
Ma Y, Liang D, Liu J, Axcrona K, Kvalheim
G, Stokke T, Nesland JM and Suo Z: Prostate cancer cell lines under
hypoxia exhibit greater stem-like properties. PLoS One.
6:e291702011.
|
|
15
|
Scholer HR, Hatzopoulos AK, Balling R,
Suzuki N and Gruss P: A family of octamer-specific proteins present
during mouse embryogenesis: evidence for germline-specific
expression of an Oct factor. EMBO J. 8:2543–2550. 1989.
|
|
16
|
Boiani M and Scholer HR: Regulatory
networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell
Biol. 6:872–884. 2005.
|
|
17
|
Monk M and Holding C: Human embryonic
genes re-expressed in cancer cells. Oncogene. 20:8085–8091.
2001.
|
|
18
|
Ugolkov AV, Eisengart LJ, Luan C and Yang
XJ: Expression analysis of putative stem cell markers in human
benign and malignant prostate. Prostate. 71:18–25. 2011.
|
|
19
|
Mallanna SK and Rizzino A: Systems biology
provides new insights into the molecular mechanisms that control
the fate of embryonic stem cells. J Cell Physiol. 227:27–34.
2012.
|
|
20
|
Tysnes BB: Tumor-initiating and
-propagating cells: cells that we would like to identify and
control. Neoplasia. 12:506–515. 2010.
|
|
21
|
Till JE: Stem cells in differentiation and
neoplasia. J Cell Physiol Suppl. 1:3–11. 1982.
|
|
22
|
Grosse-Gehling P, Fargeas CA, Dittfeld C,
Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a
biomarker for putative cancer stem cells in solid tumours:
limitations, problems and challenges. J Pathol. 229:355–378.
2013.
|
|
23
|
Missol-Kolka E, Karbanova J, Janich P,
Haase M, Fargeas CA, Huttner WB and Corbeil D: Prominin-1 (CD133)
is not restricted to stem cells located in the basal compartment of
murine and human prostate. Prostate. 71:254–267. 2011.
|
|
24
|
Lendahl U, Zimmerman LB and McKay RD: CNS
stem cells express a new class of intermediate filament protein.
Cell. 60:585–595. 1990.
|
|
25
|
Ishiwata T, Matsuda Y and Naito Z: Nestin
in gastrointestinal and other cancers: effects on cells and tumor
angiogenesis. World J Gastroenterol. 17:409–418. 2011.
|
|
26
|
Kleeberger W, Bova GS, Nielsen ME, Herawi
M, Chuang AY, Epstein JI and Berman DM: Roles for the stem cell
associated intermediate filament Nestin in prostate cancer
migration and metastasis. Cancer Res. 67:9199–9206. 2007.
|
|
27
|
Sotomayor P, Godoy A, Smith GJ and Huss
WJ: Oct4A is expressed by a subpopulation of prostate
neuroendocrine cells. Prostate. 69:401–410. 2009.
|
|
28
|
Kimbro KS and Simons JW: Hypoxia-inducible
factor-1 in human breast and prostate cancer. Endocr Relat Cancer.
13:739–749. 2006.
|
|
29
|
Mabjeesh NJ and Amir S: Hypoxia-inducible
factor (HIF) in human tumorigenesis. Histol Histopathol.
22:559–572. 2007.
|
|
30
|
Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li
Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced
aggressiveness of prostate cancer cells is linked with deregulated
expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
PLoS One. 7:e437262012.
|
|
31
|
Mathieu J, Zhang Z, Zhou W, Wang AJ,
Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, et al:
HIF induces human embryonic stem cell markers in cancer cells.
Cancer Res. 71:4640–4652. 2011.
|
|
32
|
Salnikov AV, Liu L, Platen M, Gladkich J,
Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J,
Schemme P, et al: Hypoxia induces EMT in low and highly aggressive
pancreatic tumor cells but only cells with cancer stem cell
characteristics acquire pronounced migratory potential. PLoS One.
7:e463912012.
|
|
33
|
Clark AT: The stem cell identity of
testicular cancer. Stem Cell Rev. 3:49–59. 2007.
|
|
34
|
Cizkova D, Soukup T and Mokry J: Nestin
expression reflects formation, revascularization and reinnervation
of new myofibers in regenerating rat hind limb skeletal muscles.
Cells Tissues Organs. 189:338–347. 2009.
|
|
35
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: CD133 expression is an independent prognostic marker for
low survival in colorectal cancer. Br J Cancer. 99:1285–1289.
2008.
|
|
36
|
Chambers I and Tomlinson SR: The
transcriptional foundation of pluripotency. Development.
136:2311–2322. 2009.
|
|
37
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008.
|
|
38
|
Ezeh UI, Turek PJ, Reijo RA and Clark AT:
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are
expressed in both seminoma and breast carcinoma. Cancer.
104:2255–2265. 2005.
|
|
39
|
Li L, Yu H, Wang X, Zeng J, Li D, Lu J,
Wang C, Wang J, Wei J, Jiang M and Mo B: Expression of seven
stem-cell-associated markers in human airway biopsy specimens
obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res.
32:282013.
|
|
40
|
Luo W, Li S, Peng B, Ye Y, Deng X and Yao
K: Embryonic stem cells markers SOX2, OCT4 and Nanog expression and
their correlations with epithelial-mesenchymal transition in
nasopharyngeal carcinoma. PLoS One. 8:e563242013.
|
|
41
|
Yin X, Li YW, Zhang BH, Ren ZG, Qiu SJ, Yi
Y and Fan J: Coexpression of stemness factors Oct4 and Nanog
predict liver resection. Ann Surg Oncol. 19:2877–2887. 2012.
|
|
42
|
English HF, Santen RJ and Isaacs JT:
Response of glandular versus basal rat ventral prostatic epithelial
cells to androgen withdrawal and replacement. Prostate. 11:229–242.
1987.
|
|
43
|
Lawson DA and Witte ON: Stem cells in
prostate cancer initiation and progression. J Clin Invest.
117:2044–2050. 2007.
|
|
44
|
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas
SB and Farrar WL: CD44+ CD24(−) prostate cells are early cancer
progenitor/stem cells that provide a model for patients with poor
prognosis. Br J Cancer. 98:756–765. 2008.
|
|
45
|
Yu J, Vodyanik MA, Smuga-Otto K,
Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA,
Ruotti V, Stewart R, et al: Induced pluripotent stem cell lines
derived from human somatic cells. Science. 318:1917–1920. 2007.
|
|
46
|
Pan G and Thomson JA: Nanog and
transcriptional networks in embryonic stem cell pluripotency. Cell
Res. 17:42–49. 2007.
|
|
47
|
Pereira L, Yi F and Merrill BJ: Repression
of Nanog gene transcription by Tcf3 limits embryonic stem cell
self-renewal. Mol Cell Biol. 26:7479–7491. 2006.
|
|
48
|
Suzuki A, Raya A, Kawakami Y, Morita M,
Matsui T, Nakashima K, Gage FH, Rodríguez-Esteban C and Izpisúa
Belmonte JC: Maintenance of embryonic stem cell pluripotency by
Nanog-mediated reversal of mesoderm specification. Nat Clin Pract
Cardiovasc Med. 3(Suppl 1): S114–S122. 2006.
|
|
49
|
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ,
Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations
of Oct-4 and Nanog in oral cancer stem-like cells and high-grade
oral squamous cell carcinoma. Clin Cancer Res. 14:4085–4095.
2008.
|
|
50
|
Jeter CR, Badeaux M, Choy G, Chandra D,
Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ and Tang
DG: Functional evidence that the self-renewal gene NANOG regulates
human tumor development. Stem Cells. 27:993–1005. 2009.
|
|
51
|
Xu RH, Sampsell-Barron TL, Gu F, Root S,
Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R and
Thomson JA: NANOG is a direct target of TGFbeta/activin-mediated
SMAD signaling in human ESCs. Cell Stem Cell. 3:196–206. 2008.
|
|
52
|
Danielpour D: Functions and regulation of
transforming growth factor-beta (TGF-beta) in the prostate. Eur J
Cancer. 41:846–857. 2005.
|
|
53
|
Pesce M and Scholer HR: Oct-4: control of
totipotency and germline determination. Mol Reprod Dev. 55:452–457.
2000.
|
|
54
|
Zangrossi S, Marabese M, Broggini M,
Giordano R, D’Erasmo M, Montelatici E, Intini D, Neri A, Pesce M,
Rebulla P and Lazzari L: Oct-4 expression in adult human
differentiated cells challenges its role as a pure stem cell
marker. Stem Cells. 25:1675–1680. 2007.
|
|
55
|
Lekas A, Lazaris AC, Deliveliotis C,
Chrisofos M, Zoubouli C, Lapas D, Papathomas T, Fokitis I and
Nakopoulou L: The expression of hypoxia-inducible factor-1alpha
(HIF-1alpha) and angiogenesis markers in hyperplastic and malignant
prostate tissue. Anticancer Res. 26:2989–2993. 2006.
|
|
56
|
Makarewicz R, Zyromska A and Andrusewicz
H: Comparative analysis of biological profiles of benign prostate
hyperplasia and prostate cancer as potential diagnostic, prognostic
and predictive indicators. Folia Histochem Cytobiol. 49:452–457.
2011.
|
